Site notifications

Sub menu

 
 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

1076 result(s) found, displaying 326 to 350

  • AusPAR: Tafamidis and Tafamidis meglumine

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Vyndamax (tafamidis) and Vyndaqel (tafamidis meglumine) for the treatment of transthyretin amyloid cardiomyopathy

  • AusPAR: Alpelisib

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Piqray (alpelisib), in combination with fulvestrant, for the treatment of advanced or metastatic breast cancer

  • AusPAR: Tocilizumab (rch)

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Actemra (tocilizumab) for the treatment of systemic juvenile idiopathic arthritis

  • AusPAR: Insulin aspart (rys)

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Fiasp, Fiasp Penfill, Fiasp FlexTouch (insulin aspart rys) for the treatment of diabetes mellitus

  • AusPAR: Enoxaparin sodium

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Enoxaparin sodium

  • AusPAR: Darolutamide

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Darolutamide

  • AusPAR: Remdesivir

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Remdesivir

  • AusPAR: Ribociclib succinate

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Ribociclib succinate

  • AusPAR: Ixekizumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Ixekizumab

  • AusPAR: Infliximab (rmc)

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Infliximab (rmc)

  • AusPAR: Dinutuximab beta

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Dinutuximab beta

  • AusPAR: Atezolizumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Atezolizumab

  • AusPAR: Baloxavir marboxil

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Baloxavir marboxil

  • AusPAR: Fondaparinux

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Fondaparinux

  • AusPAR: Neratinib (as maleate)

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Neratinib (as maleate)

  • AusPAR: Pembrolizumab (rch)

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Pembrolizumab (rch)

  • AusPAR: Caplacizumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Caplacizumab

  • AusPAR: Ciclosporin

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Ciclosporin

  • AusPAR: Enasidenib

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Enasidenib

  • AusPAR: Upadacitinib

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Upadacitinib

  • AusPAR: Brolucizumab (rbe)

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Brolucizumab (rbe)

  • AusPAR: Nivolumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Nivolumab

Help us improve this page